Necitumumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Necitumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target EGFR
Clinical data
Trade names Portrazza
Identifiers
CAS Number 906805-06-9 N
ATC code L01XC22 (WHO)
UNII 2BT4C47RUI YesY
KEGG D10018 N
Chemical data
Formula C6436H9958N1702O2020S42
Molecular mass 144.84 kg/mol
 NYesY (what is this?)  (verify)

Necitumumab (proposed INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[2][3][4] It was counterproductive in non-squamous non-small-cell lung carcinoma.[4][5]

References

  1. International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  2. http://www.medscape.com/viewarticle/854952?nlid=91969_3663&src=wnl_edit_newsal&uac=78316PX&impID=899999&faf=1
  3. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474278.htm
  4. 4.0 4.1 http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
  5. http://www.medscape.com/viewarticle/840768


<templatestyles src="Asbox/styles.css"></templatestyles>

<templatestyles src="Asbox/styles.css"></templatestyles>